REGAN WOODHAM: Open Payments
NPI 1467064089 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,300 in 166 payments from 19 companies in 2025. Trend: 2023 $2,270 · 2024 $2,898 · 2025 $3,300
Food & beverage: $3,300
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 30 | $496 |
| AstraZeneca Pharmaceuticals LP | 19 | $495 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 18 | $384 |
| GENZYME CORPORATION | 14 | $295 |
| Regeneron Healthcare Solutions, Inc. | 14 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $224 |
| United Therapeutics Corporation | 9 | $200 |
| Amgen Inc. | 12 | $193 |
| Viatris Specialty LLC | 7 | $145 |
| Grifols USA, LLC | 5 | $115 |
Products named: DUPIXENT, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, NUCALA, OFEV, FASENRA, YUPELRI.
Industry payments across AL — which companies pay providers there.
